We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Medivation Forks Over $570M for Rights to BioMarin’s Talazoparib
Medivation Forks Over $570M for Rights to BioMarin’s Talazoparib
California drugmaker Medivation is acquiring the worldwide rights to BioMarin’s breast cancer drug talazoparib, in a move aimed at diversifying and expanding its global oncology footprint.